ZyVersa Therapeutics, Inc. (ZVSA)
- Previous Close
6.00 - Open
5.44 - Bid 0.58 x 100
- Ask 0.64 x 100
- Day's Range
5.44 - 5.86 - 52 Week Range
5.00 - 220.85 - Volume
21,332 - Avg. Volume
250,547 - Market Cap (intraday)
44.506M - Beta (5Y Monthly) 0.58
- PE Ratio (TTM)
-- - EPS (TTM)
-1,089.70 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
8.00
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company engages in the development of VAR 200, a cholesterol efflux mediator, which is in Phase 2a clinical trial to the treatment of multiple renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic nephropathy; and IC 100, a monoclonal antibody inflammasome ASC inhibitor that is in preclinical stage for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.
www.zyversa.comRecent News: ZVSA
Performance Overview: ZVSA
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ZVSA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ZVSA
Valuation Measures
Market Cap
4.61M
Enterprise Value
1.48M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.42
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-0.10
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-12.82%
Return on Equity (ttm)
-177.53%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-106.25M
Diluted EPS (ttm)
-1,089.70
Balance Sheet and Cash Flow
Total Cash (mrq)
3.14M
Total Debt/Equity (mrq)
0.08%
Levered Free Cash Flow (ttm)
-5.46M